摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基-6-溴-2-氯吡啶 | 169833-70-9

中文名称
3-氨基-6-溴-2-氯吡啶
中文别名
2-氯-3-氨基-6-溴吡啶;6-溴-2-氯吡啶-3-胺;6-溴-3-氨基-2-氯吡啶
英文名称
6-bromo-2-chloropyridin-3-amine
英文别名
——
3-氨基-6-溴-2-氯吡啶化学式
CAS
169833-70-9
化学式
C5H4BrClN2
mdl
MFCD04971930
分子量
207.457
InChiKey
YCECOMBEVDPUJG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    117.0 to 121.0 °C
  • 沸点:
    302.4±37.0 °C(Predicted)
  • 密度:
    1.834±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    38.9
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S39
  • 危险类别码:
    R22,R37/38,R41
  • WGK Germany:
    3
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H317,H319
  • 储存条件:
    2-8°C

SDS

SDS:2c794e18f93fc939a8703edfd6201f50
查看
Material Safety Data Sheet

Section 1. Identification of the substance
6-Bromo-2-chloropyridin-3-amine
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
6-Bromo-2-chloropyridin-3-amine
Ingredient name:
CAS number: 169833-70-9

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H4BrClN2
Molecular weight: 207.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (6-Bromo-2-chloropyridin-3-amine)

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氨基-6-溴-2-氯吡啶 在 tetrafluoroboric acid 、 亚硝酸特丁酯 作用下, 以 乙腈 为溶剂, 反应 1.17h, 以24 g的产率得到6-bromo-2-chloropyridine-3-sulfonyl chloride
    参考文献:
    名称:
    INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
    摘要:
    Sultam化合物,含有它们的药物组合物,制备它们的方法,以及使用它们的方法,包括用于治疗与KEAP1-Nrf2相互作用相关的疾病状态、疾病和病况的方法,如炎症性肠病,包括克罗恩病和溃疡性结肠炎。
    公开号:
    US20200055874A1
  • 作为产物:
    描述:
    5-氨基-2-溴吡啶N-氯代丁二酰亚胺溶剂黄146 作用下, 反应 2.0h, 以93.4%的产率得到3-氨基-6-溴-2-氯吡啶
    参考文献:
    名称:
    WO2020005877A5
    摘要:
    公开号:
    WO2020005877A5
点击查看最新优质反应信息

文献信息

  • [EN] RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOLÉINE ET DE CINNOLINE SUBSTITUÉS EN 3 INHIBANT LE VRS
    申请人:JANSSEN SCIENCES IRELAND UNLIMITED CO
    公开号:WO2021214136A1
    公开(公告)日:2021-10-28
    The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    这项发明涉及具有抗病毒活性的式(I)化合物,特别是对呼吸道合胞病毒(RSV)复制具有抑制活性的化合物。该发明还涉及包含这些化合物的药物组合物,以及用于治疗呼吸道合胞病毒感染的化合物。
  • SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
    申请人:Arizona Board of Regents on Behalf of the University of Arizona
    公开号:US20200039989A1
    公开(公告)日:2020-02-06
    This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.
    这项发明属于药物化学领域。具体来说,该发明涉及一类新型小分子,具有6,5-杂环结构(例如,具有咪唑吡啶、咪唑吡嘧啶、咪唑吡嗪、咪唑吡啶嗪、咪唑三嗪、苯并咪唑、苯并三唑、苯并异嗪、嘌呤、吲唑、三唑三嗪、三唑吡啶嗪、三唑吡嘧啶、三唑吡嗪、三唑四嗪、三唑吡啶、吡唑吡嗪、吡唑吡嘧啶、吡唑吡啶嗪、吡唑三嗪、吡唑吡啶、异嗪吡嗪、异嗪吡嘧啶、异嗪吡啶嗪、异嗪三嗪、或异嗪吡啶结构),其作为DYRK1A、DYRK1B和Clk-1的抑制剂,以及它们作为治疗阿尔茨海默病、唐氏综合征、糖尿病、胶质母细胞瘤、自身免疫疾病、癌症(例如,胶质母细胞瘤、前列腺癌)、炎症性疾病(例如,气道炎症)和其他疾病的治疗药物的用途。
  • [EN] NEW IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS DUAL DYRK1/CLK1 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS D'IMIDAZO[4,5-B]PYRIDINE UTILISÉS COMME INHIBITEURS DE DYRK1/CLK1 DOUBLES
    申请人:SERVIER LAB
    公开号:WO2017055530A1
    公开(公告)日:2017-04-06
    (Formula I) Compounds of formula (I) usefull for the treatment of cancer, neurodegenerative disorders and metabolic disorders.
    化合物的化学式(I)可用于治疗癌症、神经退行性疾病和代谢性疾病。
  • Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
    作者:Csaba Weber、Melinda Sipos、Attila Paczal、Balazs Balint、Vilibald Kun、Nicolas Foloppe、Pawel Dokurno、Andrew J. Massey、David Lee Walmsley、Roderick E. Hubbard、James Murray、Karen Benwell、Thomas Edmonds、Didier Demarles、Alain Bruno、Mike Burbridge、Francisco Cruzalegui、Andras Kotschy
    DOI:10.1021/acs.jmedchem.1c00023
    日期:2021.5.27
    DYRK1A ATP site with very high efficiency, although with limited selectivity. Structure-guided optimization cycles enabled us to convert this fragment hit into potent and selective DYRK1A inhibitors. Exploiting the structural differences in DYRK1A and its close homologue DYRK2, we were able to fine-tune the selectivity of our inhibitors. Our best compounds potently inhibited DYRK1A in the cell culture
    激酶 DYRK1A 由于其在多种疾病中的作用而成为药物发现项目的一个有吸引力的靶点。通过片段筛选,我们鉴定了一种简单的联芳基化合物,该化合物以非常高的效率与 DYRK1A ATP 位点结合,但选择性有限。结构引导的优化循环使我们能够将此片段转化为有效的选择性 DYRK1A 抑制剂。利用 DYRK1A 及其密切同源物 DYRK2 的结构差异,我们能够微调抑制剂的选择性。我们最好的化合物可在细胞培养物和体内有效抑制 DYRK1A,并表现出类似药物的特性。在卵巢癌模型中,体内DYRK1A 的抑制转化为剂量依赖性肿瘤生长抑制。
  • [EN] PESTICIDALLY ACTIVE POLYCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS<br/>[FR] DÉRIVÉS POLYCYCLIQUES À ACTIVITÉ PESTICIDE COMPORTANT DES SUBSTITUANTS CONTENANT DU SOUFRE
    申请人:SYNGENTA PARTICIPATIONS AG
    公开号:WO2016071214A1
    公开(公告)日:2016-05-12
    Polycyclic Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    式(I)的多环化合物,其中取代基如权利要求书中定义的那样,以及这些化合物的农药可接受的盐、立体异构体、对映异构体、互变异构体和N-氧化物,可用作杀虫剂,并可按照已知的方法制备。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-